Cellectis - ADR
CLLS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$117.76M
Close$
$-1.33
213.9% downside
Current Fair Value
213.9% downsideOvervalued by 213.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $117.76 Million |
|---|---|
| Enterprise Value | $257.68 Million |
| Earnings per Share | $-0.68 |
| Beta | 3 |
| Outstanding Shares | 100,647,451 |
Return
| Return on Equity | -159.71% |
|---|---|
| Return on Assets | -24.53% |
| Return on Invested Capital | -37.36% |
Valuation & Multiples
| P/E Ratio | -1.78 |
|---|---|
| PEG | 19.29 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.55 |
| Enterprise Value to EBIT | -5.21 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.68 |
| Debt to Equity | 4.27 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.26
Consensus analyst estimateRevenue Estimate
$11.05 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.20
Consensus analyst estimateRevenue Estimate
$15.19 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.42%▼ 0.78% |
|---|---|
| Total Invested | $28.45M▼ 12.52% |
| Investors Holding | 27▼ 6.00% |
About Cellectis
227 employees
CEO: Andre Choulika
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to dis...